|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2003-4-18
|
|
pubmed:abstractText |
Hypermethylation and inactivation of tumor suppressor genes by the enzyme DNA methyltransferase may lead to neoplastic transformation. MG98, a phosphorothioate antisense oligodeoxynucleotide that is a specific inhibitor of mRNA for human DNA methyltransferase 1 (DNMT1), was evaluated in a phase I study.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
766-74
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12702532-Adult,
pubmed-meshheading:12702532-Aged,
pubmed-meshheading:12702532-Aged, 80 and over,
pubmed-meshheading:12702532-Area Under Curve,
pubmed-meshheading:12702532-DNA (Cytosine-5-)-Methyltransferase,
pubmed-meshheading:12702532-Dose-Response Relationship, Drug,
pubmed-meshheading:12702532-Drug Administration Schedule,
pubmed-meshheading:12702532-Enzyme Inhibitors,
pubmed-meshheading:12702532-Female,
pubmed-meshheading:12702532-Humans,
pubmed-meshheading:12702532-Male,
pubmed-meshheading:12702532-Middle Aged,
pubmed-meshheading:12702532-Neoplasms,
pubmed-meshheading:12702532-Oligonucleotides, Antisense,
pubmed-meshheading:12702532-RNA, Messenger,
pubmed-meshheading:12702532-Thionucleotides
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly.
|
|
pubmed:affiliation |
Ottawa Regional Cancer Centre, Ottawa, ON, Canada.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
